MLO State of the Industry MDX 2024 Question Title * 1. What is your title/position within the lab facility? (Select only one) Lab Manager, Administrator, Supervisor Lab Director Pathologist, Physician Section Manager, Dept Head Compliance manager, QA Coordinator Clinical chemist MLS-Medical laboratory scientist MLT-Medical laboratory technician Medical laboratory assistant POCT coordinator Group practice manager, Administrator Microbiologist Other (please specify) Question Title * 2. What type of facility best describes where you work? (Select only one) Hospital lab/Health system lab Reference lab Physician office lab Academic/Research lab Specialty lab (i.e., blood banking facility) Other (please specify) Question Title * 3. In 2024, what has been the average number of molecular-based tests (non-COVID-19) performed by your lab daily? (Select only one) 0-100 101-200 201-300 301-400 401+ Question Title * 4. How much has respiratory testing increased at your lab in 2024? (Select only one) 0-25 percent 26-50 percent 51-75 percent 76-100 percent 101+ percent It has decreased Question Title * 5. Has your lab experienced issues with maintaining a supply of testing products due to supply chain issues? (Select only one) Yes, a lack of testing supplies has impeded our testing capacity at times. No, we have adequate testing supplies to meet testing demands. Question Title * 6. What testing supplies are you having trouble sourcing due to supply chain issues? (Select all that apply) Blood collection tubes Blood culture transfer devices Controls/Reagents Culture media PPE Pipettes/Pipette tips Swabs/Consumables Testing kits for SARS-CoV-2 Transport media Urine testing supplies Winged blood collection sets Lab plastic supplies not noted above None Other (please specify) Question Title * 7. What types of molecular diagnostic tests do you use in your laboratory? (Select all that apply) Reverse transcriptase quantitative polymerase chain reaction (rRT-qPCR) Reverse transcription loop-mediated isothermal amplification (RT-LAMP) Recombinase polymerase amplification (RPA) CRISPR-based diagnostics DNA/Genetic testing Flow cytometry Liquid biopsy Mass Spectrometry Next generation sequencing Rapid antigen test Rapid molecular test None Other (please specify) Question Title * 8. Which of the following three molecular diagnostic test companies do you use the most? (Select three) Abbott Agena Bioscience Agilent Technologies BD Beckman Coulter bioMérieux Bio-Rad Bio-techne/Asuragen Cepheid DiaSorin ELITech Group Euroimmun/Revvity GenMark Hardy Diagnostics Hologic Illumina LabCorp LumiraDx Qiagen Quest QuidelOrtho Roche Seegene Siemens Standard BioTools Streck Thermo Fisher Scientific Other (please specify) Question Title * 9. How do you handle questionable results with molecular tests? (Select only one) Repeat the test Repeat the test with different employee/equipment/test Verify all pre-analytical, analytical, and/or post-analytical steps are performed correctly Send results to another lab for verification and second test Other (please specify) Question Title * 10. What steps does your lab take to reduce the number of potential false positive test results? (Select top three) Repeat the test with the same sample and new extractions Repeat the test with another method and compare results Verify all pre-analytic, analytic, post-analytic steps are performed correctly Refer to quality assurance program guidance Decontaminate work/test area per laboratory procedures None Other steps not listed above, please elaborate Question Title * 11. Is your lab developing tools/processes to manage decreased access to LDTs? Yes No Please elaborate Question Title * 12. If you would like to be contacted to contribute to this article or other future articles, please provide the following: First Name Last Name Title Company Phone Email Done